FIELD: medicine, oncology.
SUBSTANCE: invention can be used in the treatment of non-APL (acute promyelocytic leukemia) acute myelocytic leukemia (non-APL AML). The method includes administering a combination of tamibarotene and a second therapeutic agent to a subject having non-ATL AML, wherein the cancer cells contained in a biological sample from the said subject contain an IRF8 biomarker and/or a RARA biomarker, the said second therapeutic agent being: azacitidine, midostaurin, cytarabine, daunorubicin, methotrexate, idarubicin, sorafenib, decitabine, quisartinib, ABT199, JQ1, prednisone, SAHA, GSKJ4, or EPZ6438.
EFFECT: use of the invention makes it possible to increase the effectiveness of the treatment of patients with non-APL AML, in which cancer cells express the IRF8 biomarker, due to the synergistic effect of the combination.
29 cl, 21 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PATIENT STRATIFICATION FOR TREATMENT WITH AGONISTS OF RETINOIC ACID ALPHA-RECEPTORS | 2016 |
|
RU2789374C2 |
| METHODS OF TREATING, DIAGNOSING AND PREDICTING A HEMATOLOGIC MALIGNANT NEOPLASM | 2015 |
|
RU2727418C2 |
| METHODS FOR TREATING NEUTROPENIA USING RETINOID AGONISTS | 2013 |
|
RU2650962C2 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| METHOD FOR TREATING NIDDM BY RXR AGONISTS | 1996 |
|
RU2191007C2 |
| COMPOSITIONS INCREASING THE NUMBER OF COPIES OF THE VECTOR (VCN), AND METHODS OF USING | 2017 |
|
RU2744603C2 |
| METHODS OF INFLUENCING TRANSCRIPTION CONTROL IN SUPER-ENHANCER AREAS | 2015 |
|
RU2737508C2 |
| COMPOSITIONS AND METHODS OF STEM CELL TRANSPLANTATION | 2019 |
|
RU2809803C2 |
| METHOD FOR DIAGNOSING ACUTE LEUKEMIA AND KITS FOR ITS IMPLEMENTATION | 2021 |
|
RU2806591C2 |
| RENAL CELL POPULATIONS AND THEIR USE | 2013 |
|
RU2805243C2 |
